Research · Division of Rheumatology, UCT

Questions the centre
hasn't thought to ask

Building the evidence base for rheumatic and musculoskeletal disease in Africa — and training the clinicians who will carry it forward.

Why we do this

Research from where the burden is

Rheumatology is a rapidly evolving field, with a growing set of diagnostic tools and new therapies. Clinicians in resource-constrained settings such as ours need to explore novel ways to deliver excellent clinical care to their patients, whilst advancing understanding of the pathogenesis and burden of musculoskeletal diseases affecting Africans. Excitingly, the relevance of clinical and laboratory research from the “developing world” is increasingly recognised. Studies assessing cost-effective strategies in resource-constrained settings might also provide important lessons for the recession-hit healthcare systems of many developed countries.

Young South African clinicians are frequently overwhelmed by the clinical burden of heavy patient-loads and long working hours, yet with appropriate supervision, can undertake novel and meaningful research that informs clinical practice. Hence we believe that mentorship of young health care workers is vital, so that young clinicians are attracted to academic careers. This will amend the dearth of published work and health information arising from Africa and other parts of the developing world.

Importantly, these research projects have academic impact by providing opportunities for clinicians and scientists from different disciplines to collaborate. This enriches the exploration of each disease, and offers excellent academic outcomes in terms of Master in Medicine (MMed), Master in philospophy (M Phil) and Doctor of Philosophy (PhD) degrees.

Clinicians in resource-constrained settings such as ours need to explore novel ways to deliver excellent clinical care to their patients.

Division of Rheumatology, UCT
Flagship project

The “Hands On” Registry

Prospective longitudinal registry

Chronic rheumatic and musculoskeletal disorders (RMD’s) are an important and growing cause of disability and impaired quality of life in South Africans, yet there is little published work on these diseases or the impact of these diseases on patients’ lives. “Hands On” is a prospective longitudinal registry collating demographic, clinical and genetic data of patients with RMD’s. Participants are recruited from the rheumatology outpatient clinics of Groote Schuur Hospital, a tertiary academic hospital in the Western Cape, South Africa and are reviewed annually.

Anticipated outcomes

01

This project will provide high quality contemporary data on the burden of RMD’s in the Western Cape, South Africa.

02

A biobank of serum and genetic samples to analyse in future sub-studies.

03

This data will hopefully that will lead to development of strategies to improve clinical care and lifestyle interventions for patients with RMD’s.

04

This registry will serve as a platform for future interventional studies, qualitative interviews and clinical trials.

05

This registry will enhance the research capacity of the Department by offering employment, training and experience to the study coordinator and data capturer.

06

The registry will lead to post-graduate degrees for clinical researchers allowing detailed study of specific diseases, or aspects of health-related Quality of Life across diseases.

07

In time it is hoped that this registry will be used as a template by other academic rheumatology centres in South Africa and elsewhere in Africa. Multicentered data will allow comparison of patients across geographical regions, and will also allow analysis of uncommon manifestations.

Current projects

Studies running from the “Hands On” registry

  1. 01Discordance between the patient's global assessment and physician's global assessment and their drivers in South African patients with rheumatoid arthritis.
  2. 02Anxiety amongst rheumatology patients attending Groote Schuur Hospital.
  3. 03Health-related quality of life across rheumatic diseases at Groote Schuur Hospital.
  4. 04High burden of functional disability, impaired health-related quality of life and unmet needs amongst South Africans with gouty arthritis.
  5. 05Cigarette smoking amongst rheumatoid arthritis patients in a tertiary centre in South Africa.
  6. 06Gender differences amongst rheumatology patients attending Groote Schuur Hospital.
  7. 07Understanding pain amongst rheumatology patients attending Groote Schuur Hospital.
  8. 08Determinants of patient and physician global assessment of disease activity and their discrepancies amongst South Africans with rheumatoid arthritis.
  9. 09Understanding fatigue in rheumatoid arthritis patients in South Africa: prevalence, impact, and contributing factors.
  10. 10Clinical, laboratory and imaging profiles of neuropsychiatric systemic lupus erythematosus at Groote Schuur Hospital.
  11. 11Systemic sclerosis: clinical features and health-related quality of life in systemic sclerosis.
Publications

Published work

Four decades of published work from the division and its collaborators — from bone-density and lupus studies in the late 1980s, through the African Lupus Genetics Network and global rheumatoid arthritis epidemiology, to the South African Rheumatism and Arthritis Association’s 2024 national treatment guidelines. Much of it asks how good rheumatology care can be delivered where resources are short.

2026

  1. Didi SA and Hodkinson B (2026) Discordance between patient and physician global assessments amongst South Africans with rheumatoid arthritis. Front. Musculoskelet. Disord. 4:1882633.
  2. Le Roux SJ, Bagula H, Van Zyl-Smit R, Hodkinson B. Cigarette smoking habits and attitudes among rheumatoid arthritis patients at a tertiary centre in South Africa. J Coll Med S Afr. 2026;4(1)

2025

  1. Development of a NSAID decision-tool for perioperative pain management in adult orthopaedic patients: a Delphi consensus study. SAOJ 2025; 24 (3)
  2. Dey D, Hodkinson B. Bridging the rheumatology resource gap in Africa. Clin Rheumatol. 2025 Feb 20. doi: 10.1007/s10067-025-07362-7

2024

  1. B Hodkinson, E van Duuren and A Maharaj et al. Introduction to the South African Rheumatism and Arthritis Association 2024 guidelines. SAMJ, S. Afr. med. j.. 2024. Vol. 114(9):14-16. DOI: 10.7196/samj.2024.v114i9.1429
  2. Benitha, Romela & Maharaj, Ajesh & Makan, Kavitha & Potts, J & Lai, Anita & Carter, Richard & Dam, M & Hodkinson, Bridget. (2024). South African Rheumatism and Arthritis Association 2024 guidelines for the management of peripheral spondyloarthritis. South African Medical Journal. 114. 17-22. 10.7196/SAMJ.2024.v114i10.2669.
  3. Maharaj, Ajesh & Benitha, Romela & Makan, Kavita & du Toit, Riëtte & Haasbroek, D & Balton, Charlene & Govender, P & Dam, M & Paruk, Farhanah & Hodkinson, Bridget. (2024). South African Rheumatism and Arthritis Association 2024 guidelines for the management of axial spondyloarthritis. South African Medical Journal. 114. 12-16. 10.7196/SAMJ.2024.v114i10.2668.
  4. Tarr, G & Gardiner, E & Seboka, Mpoti &. Hodkinson, Bridget. (2024). South African Rheumatism and Arthritis Association 2024 updated guidelines for the management of rheumatoid arthritis. 114. 17. 10.7196/SAMJ.2024.v114i9.2598.
  5. Van Duuren, E & Potts, J & Brijlal, U & Botha, S & Didi, S & Dam, M & Chinniah, K & Hodkinson, B. (2024). South African Rheumatism and Arthritis Association 2024 guidelines for the use of biologic and targeted synthetic disease-modifying antirheumatic drugs. 114. 24-36. 10.7196/samj.2024.v114i9.2559.

2023

  1. Ahmed Mohammed Awad Eltoum, Scott Christiaan, Gcelu Ayanda, Steffen Jonel, Isaacs Thuraya, Hodkinson Bridget. Screening practices, efficacy, safety and adherence to biologic therapies in a South African tertiary hospital. Frontiers in Musculoskeletal Disorders. 2023 https://www.frontiersin.org/articles/10.3389/fmscd.2023

2022

  1. Feldman C, Dlamini S, Richards GA, Black J, Butler ILC, Cutland C, Hefer E, Hodkinson B, Kok A, Manga P, Meiring S, Molaudzi M, Moosa MS, Parker S, Peter J, van Vuuren C, Verburgh E, Watermeyer G. A comprehensive overview of pneumococcal vaccination recommendations for adults in South Africa, 2022. J Thorac Dis. 2022 Oct;14(10)
  2. Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, Alpizar-Rodriguez D, Lauper K. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022 Oct;18(10):591-602.
  3. Palalane E, Alpizar-Rodriguez D, Botha S, Said -Hartley Q, Calligaro G, Hodkinson B. Interstitial Lung Disease in patients with Connective Tissue Disease: subtypes, clinical features and comorbidities in South Africa. AJTCCM June 2022
  4. Ramona Govender , Bridget Hodkinson . Poor Adherence to Indications for Antineutrophil Cytoplasmic Antibody Testing in a South African Tertiary Hospital. INNOSC Theranostics and Pharmacological Sciences 2022, 5(2), 15–21.

2020

  1. Ahmed, M & Hodkinson, B. (2020). Two Musculoskletal Complications of HIV Infection. Journal of Infectious Diseases & Case Reports. 1-2. 10.47363/JIDSCR/2020(1)121.
  2. Hodkinson B, Singh P, Gcelu A, Molano WB, Pons-Estel G, Alpízar-Rodríguez D. Navigating COVID-19 in the developing world. Clin Rheumatol. 2020 Jul;39(7):20392042.
  3. Solomon A, Stanwix AE, Castañeda S, Llorca J, Gonzalez-Juanatey C, Hodkinson B, Romela B, Ally MMTM, Maharaj AB, Van Duuren EM, Ziki JJ, Seboka M, Mohapi M, Jansen Van Rensburg BJ, Tarr GS, Makan K, Balton C, Gogakis A, González-Gay MA, Dessein PH. Points to consider in cardiovascular disease risk management among patients with rheumatoid arthritis living in South Africa, an unequal middle income country. BMC Rheumatol. 2020 Jun 16;4:42.

2019

  1. Mohammed AGA, Gcelu A, Moosajee F, Botha S, Kalla AA Immune Mediated Necrotizing Myopathy: Where do we Stand? Curr Rheumatol Rev. 2019;15(1):2326.
  2. Phuti A, Hodkinson B, Tikly M, Schneider M. 'The feeling of not being entitled to something': fertility, pregnancy, and sexuality among women with systemic lupus erythematosus in South Africa. Scand J Rheumatol. 2019 Oct 4:1-7.
  3. Phuti A, Schneider M, Makan K, Tikly M, Hodkinson B. Living with systemic lupus erythematosus in South Africa: a bitter pill to swallow. Health Qual Life Outcomes. 2019 Apr 16;17(1):65.

2018

  1. Gcelu A, Deshpande G, Shaboodien G, Spracklen TF, Kalla A, Tikly M, Mayosi BM, Hodkinson B. Mutations of FAM111B gene are not associated with systemic sclerosis. Sci Rep. 2018 Oct 30;8(1):15988. doi:10.1038/s41598-018-34341-7
  2. Phuti A, Schneider M, Tikly M, Hodkinson B.Living with systemic lupus erythematosus in the developing world. Rheumatol Int. 2018 Sep;38(9):1601-1613.

2017

  1. GEO-RA Group. Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey. Clin Rheumatol. 2017 Mar;36(3):485-497. doi: 10.1007/s10067-016-3481-9.

2016

  1. Adizie T, Moots RJ, Hodkinson B, French N, Adebajo AO. Inflammatory arthritis in HIV positive patients: A practical guide. BMC Infect Dis. 2016 Mar 1;16:100.
  2. Ameh OI, Kengne AP, Jayne D, Bello AK, Hodkinson B, Gcelu A, Okpechi IG. Standard of treatment and outcomes of adults with lupus nephritis in Africa: a systematic review. Lupus 2016 Oct;25(11):1269-77
  3. B Hodkinson, N Osman, S Botha-Scheepers. HIV Infection and Osteoarticular Tuberculosis: Strange Bedfellows. Case Reports in Rheumatology 2016;2016:5718423
  4. B Hodkinson. D Mapiye. D Jayne. A Kalla. N Tiffin. I Okpechi. The African Lupus Genetics Network (ALUGEN) registry: standardized, prospective follow-up studies in African patients with systemic lupus erythematosus. Lupus March 2016. 25: (3) 325-33
  5. Hodkinson B, Magemoro KR and Tikly M. Combination Leflunomide and Methotrexate in Refractory RA: A Biologic Sparing Approach. Therapeutic Advances in Musculoskeletal Disease. 2016 Oct;8(5):172-179
  6. Hodkinson B, Okpechi I and Botha-Scheepers S. Chronic Large Joint Synovitis in Systemic Lupus Erythematosus: Finding What You Look For. Journal of Rheumatic Diseases and Treatment, 2016,2 ( 2): 2469-5726

2015

  1. Gcelu A, Kalla AA.Musculoskeletal disorders--disease burden and challenges in the developing world. S Afr Med J. 2015 Dec;105(12):1070-1.
  2. Hodkinson B, Makda MA. Evidence-based treatment of systemic lupus erythematosus and its complications. S Afr Med J. 2015 Dec;105(12):1075.
  3. Tikly M, Hodkinson B, Dheda K.Biologic therapy for rheumatoid arthritis in developing countries--a place for non-TNF inhibitors as first-line treatment? Rheumatology (Oxford).2015 ;54(2):208-9

2014

  1. Gcelu A. Rheumatic diseases and pregnancy. S Afr Med J. 2014 Sep;104(9):643
  2. Hodkinson B, Tikly M, Adebajo A.Rheumatoid arthritis in the developing world: stepping up to the challenge.Clin Rheumatol. 2014 ;33(9):1195-6
  3. Ally M, Hodkinson B. Rheumatoid arthritis. S Afr Fam Pract. 2014;56(3):166-171. doi:10.1080/20786204.2014.932547
  4. Myat Tun Lin Nyo; Asgar Ali Kalla. Thrombocytopenia and thrombosis: a doubleedged sword. Clin Rheumatol. 2014. 33:587–590.
  5. Tarr G, Hodkinson B, Reuter H. Superheroes in autoimmune warfare: biologic therapies in current South African practice. S Afr Med J. 2014 Nov;104(11):787-91. Review.

2013

  1. B Hodkinson; E van Duuren; C Pettipher; A A Kalla. South African recommendations for the management of rheumatoid arthritis: An algorithm for the standard of care in 2013. S Afr Med J 2013. 103(8):576-585.
  2. Tiffin N, Hodkinson B, Okpechi I.Lupus in africa: can we dispel the myths and face the challenges? Lupus. 2013 2013 ;103:576-85.

2011

  1. A A Kalla. Musculoskeletal Examination. CME Journal. August 2011.
  2. A Gcelu; A A Kalla. Early Rheumatoid Arthritis. CME Journal. August 2011.
  3. A Kalla. Guest Editor. Continuing Medical Education Journal of SA. 2011.

2010

  1. Arendse R, Gcelu A, Scott C, Beighton P, Kalla A. Do the radiographic features of joint destruction in tophaceous gout imply a different pathophysiology to that of rheumatoid and psoriatic arthritis? Clin Rheumatol. 2010 Oct;29(10):1181-3
  2. Regan Arendse, Ayanda Gcelu, Christiaan Scott, Peter Beighton, Asgar Kalla. Do the radiographic features of joint destruction in tophaceous gout imply a different pathophysiology to that of rheumatoid and psoriatic arthritis? Clinical Rheumatology. October 2010, Volume 29, pp 1181-1183

2009

  1. Constant Deborah; Rosenberg Lynn; Zhang Yuqing; Cooper Diane; Kalla Asgar A.; Micklesfield Lisa; Hoffman Margaret. Quantitative Ultrasound in Relation to Risk Factors for Low Bone Mineral Density in South African Pre-Menopausal Women. http://hdl.handle.net/2144/3425. 2009.

2008

  1. Handa, R., Kalla, A.A. and Maalouf, G. Osteoporosis in developing countries. Best Practice and Research Clinical Rheumatology, 2008. 22:, 693-708.

2007

  1. Lynn Rosenberg, Yuqing Zhang, Deborah Constant, Diane Cooper, Asgar Kalla, Margaret Hoffman. Bone status after cessation of use of injectable progestin contraceptives. Contraception. 2007 Dec 76(6):425-31.

2003

  1. Brighton S, Tikly M, Kalla AA, Mody GM. Guidelines for the treatment of osteoarthritis. (South African Medical Journal. 2003.
  2. Kalla AA, Stanwix A, Gotlieb D, Asherson RA, Mody GM. Rheumatoid Arthritis: Clinical Guideline 2003. South African Medical Journal. 2003; 93: 991-1011.
  3. Kalla AA, Stanwix A, Gotlieb G, Asherson R, Mody GM. Guidelines for the treatment of rheumatoid arthritis. SA Med J. 2003; December.
  4. Kalla AA, Tikly M. Rheumatoid arthritis in the developing world. Best Pract Res Clin Rheumatol. 2003; 17: 863-75.
  5. Meyers OL, Cassim B, Kalla AA, Mody GM. Guidelines for the treatment of Gout. (South African Medical Journal. 2003).
  6. Micklesfield L, Rosenberg L, Cooper D, Hoffman M, Kalla A, Stander I,Lambert E. Bone mineral density and lifetime physical activity in South African women. Calcified Tissue International, 2003; Sept 10.
  7. Mody GM, Tikly M, Kalla AA, Meyers OL. Approach to Arthritis: Clinical Guideline 2003. South African Medical Journal. 2003; 93: 949-960.

2002

  1. Kalla AA, Bewerunge L, Langley A, Meyers OL, Fataar AB. Trabecular bone density in premenopausal rheumatoid arthritis patients. South African Medical Journal. 2002; 92 (1): 62-68
  2. Myllykangas-Luosujarvi R, Lu HS, Chen SL, Choon D, Amante C, Chow CT, Pasero G, Genti G, Sarembock B, Zerbini CA, Vrijens F, Moan A, Rodgers DB, De Tora L, Laurenzi M; Naproxen 901 OF study group Naproxen 901 OC study group. Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Scand J Rheumatol 2002; 31: 337-44.

2001

  1. Kalden JR, Scott DL, Smolen JS, Schattenkirchner M, Rozman B, Williams BD, Kvien TK, Jones P, Williams RB, Oed C, Rosenburg R; European Leflunomide Study Group. Improved functional ability in patients with rheumatoid arthritis—longterm treatment with leflunomide versus sulfasalazine. J Rheumatol. 2001; 28: 1983-91.
  2. Larsen A, Kvien TK, Schattenkirchner M, Rau R, Scott DL, Smolen JS, Rozman B, Westhovens R, Tikly M, Oed C, Rosenburg R; European Leflunomide Study Group. Slowing disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. Scandanavian J of Rheumatol 2001; 30 : 135-142.
  3. Wilder-Smith CH, Hill L, Spargo K, Kalla A. Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in with NSAID's: a randomised study comparing analgesia, antinociception and effects. Pain. 2001; 91: 23-31.

2000

  1. Burch VC, Isaacs S, Kalla AA. Ethnicity and patterns of spondyloarthritis in South Africa – analysis of 100 patients. J Rheumatol. 2000; 26: 2195 – 200.
  2. Sharp JT, Strand V, Leung H, Hurley G, Loew-Friedrich, Leflunomide Rheumatoid Arthritis Investigators Group. Treatment with leflunomide slows radiographic progression in rheumatoid arthritis. Arthritis and Rheumatism 2000; 43 : 495-505.
  3. Tikly M, Kalla AA, Mody GM. Rheumatology in Africa at the turn of the century – Report on the third AFLAR Congress, Stellenbosch, South Africa. J of Clin Rheumatol 2000; 4: 103-106.

1999

  1. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I, Oed C, Rosenburg R, and the European Leflunomide study group. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis : a double-blind, randomised, multicentre trial. Lancet, 1999; 353 : 259266.
  2. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Caldwell J, Kaine J, Sharp J, Hurley F, Loew-Friedrich I, Leflunomide Rheumatoid Arthritis Investigators Group. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med. 1999 Nov 22;159(21):2542-50.

1997

  1. Lemmer ER, O’Malley BD, Levitt NS, Halkett JA, Kalla AA, Krige JEJ. Bile duct stricture complicating systemic lupus erythematosus. J Clin Gastroenterol. 1997; 25: 708-10

1995

  1. Kalla AA, Meyers OL, Laubscher R. Prevalence of metacarpal osteopenia in young rheumatoid arthritis patients. Clin Rheumatol. 1995; 14: 617-25.
  2. Kalla AA, Meyers OL, van Wyk Kotze TJ, Laubscher R. Corticosteroid therapy and bone mass - comparison of systemic lupus erythematosus and rheumatoid arthritis. South African Medical Journal. 1995; 84 (7): 404-409.
  3. Kalla AA, Smith PR, Brown GMM, Meyers OL, Chalton D. Responsiveness of Keitel function index compared with laboratory measures of disease activity in rheumatoid arthritis. B J Rheumatol. 1995; 34: 141-9.

1994

  1. Kalla AA, Fataar AB, Bewerunge L. Age-related loss of bone in South African females using the QDR 1000 system. South African Medical Journal. 84 (7): 398404; 1994.
  2. Kalla AA, Tooke AFR, Bhettay E, Meyers OL. Risk-benefit assessment of slow-acting anti-rheumatic drugs in rheumatoid arthritis. Drug Safety. 1994; 11: 21-36.
  3. Woolf D, Voigt MD, Jaskiewitz K, Kalla AA. Pulmonary hypertension associated with non-cirrhotic portal hypertension in systemic lupus erythematosus. Postgrad Med J. 1994; 70: 41-3

1993

  1. Kalla AA, Fataar AB, Jessop SJ, Bewerunge L. Loss of trabecular bone mineral density in systemic lupus erythematosus. Arthritis Rheum. 1993; 36: 1726-1734.

1992

  1. Bhettay EM, Kalla AA. Myasthenia gravis associated with seropositive juvenile arthritis. Clin Exp Rheumatol. 1992; 10 (5): 499-501.
  2. Gongryp L, Kalla AA. Chloroquine induced vitiligo in a patient with juvenile onset rheumatoid arthritis. Br J Rheumatol. 1992; 31 (11): 790-1.
  3. Kalla AA, Brown GMM, Meyers OL. Nutritional status in rheumatoid arthritis effects of disease activity, corticosteroid therapy and functional impairment. South African Medical Journal. 1992; 82 (6): 411-4.
  4. Kalla AA, van Wyk Kotze TJ, Meyers OL. Metacarpal bone mass in systemic lupus erythematosus. Clinical Rheumatology (Belgium). 1992; 11 (4): 475-82.

1991

  1. Kalla AA, Meyers OL, Chalton D, Heath S, Brown GM, Smith PR, Burger M. Increased metacarpal bone mass following 18 months of slow-acting antirheumatic drugs for rheumatoid arthritis. Br J Rheumatol. 1991; 30: 91-100.

1990

  1. Kalla AA, Isaacs S, Jessop SJ, Meyers OL. Corticosteroid effects on parathormone and ionised calcium levels in systemic lupus erythematosus and rheumatoid arthritis. Osteoporosis 1990. (Ed) Christiansen C, Overgaard K. Handelstrykkeriet Aalborg ApS. Aalborg, Denmark. 1990; 1600-1604.

1989

  1. Kalla AA; Meyers OL; Parkyn ND; Kotze TJ v W. Osteoporosis Screening Radiogrammetry Revisited. B J Rheumatol. 1989; 28(6): 511-517.
  2. Martell RW, DuToit ED, Kalla AA, Meyers OL. Association of rheumatoid arthritis with HLA in three South African populations - Whites, Blacks and a population of mixed ancestry. South African Medical Journal. 1989; 76: 189-190.

1988

  1. Kalla AA, Kotze TJvW, Meyers OL, Parkyn ND. Clinical assessment of disease activity in rheumatoid arthritis: evaluation of a functional test. Ann Rheum Dis 1988; 47: 773-779.

1986

  1. Kalla AA, Learmonth ID, Klemp P. Early Treatment of Avascular Necrosis in Systemic Lupus Erythematosus. Ann Rheum Dis 1986; 45: 649-652.

Year not stated

  1. I Okpechi, C Swanepoel, B Rayner, A Gcelu, B Hodkinson, A Kalla, Systemic lupus erythematosus (SLE) in Cape Town: A precursory report of the ALUGEN registry. Clinical Rheumatology 32, S140-S141

No publications match your search.

Interested in collaborating?

These projects offer opportunities for clinicians and scientists from different disciplines to work together, and lead to MMed, MPhil and PhD degrees. If you would like to discuss a collaboration or postgraduate supervision, get in touch with the division.

Contact the division